Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aprea Therapeutics Inc (APRE)

Aprea Therapeutics Inc (APRE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,371
  • Shares Outstanding, K 21,974
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,130 K
  • 60-Month Beta 0.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade APRE with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.65
  • Most Recent Earnings -0.36 on 05/16/22
  • Next Earnings Date 05/19/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 373.65% ( -71.98%)
  • Historical Volatility 141.03%
  • IV Percentile 97%
  • IV Rank 41.71%
  • IV High 773.73% on 05/18/22
  • IV Low 87.33% on 08/17/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 4
  • Volume Avg (30-Day) 53
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 13,304
  • Open Int (30-Day) 14,489

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.40
  • Number of Estimates 1
  • High Estimate -0.40
  • Low Estimate -0.40
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.6200 +6.79%
on 05/20/22
1.6351 -59.51%
on 04/26/22
-0.9279 (-58.36%)
since 04/25/22
3-Month
0.6200 +6.79%
on 05/20/22
2.0400 -67.54%
on 04/05/22
-1.0779 (-61.95%)
since 02/25/22
52-Week
0.6200 +6.79%
on 05/20/22
7.8000 -91.51%
on 06/16/21
-3.4079 (-83.73%)
since 05/25/21

Most Recent Stories

More News
Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports First Quarter 2022 Financial Results

BOSTON, May 16, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 0.6661 (-0.34%)
First Week of May 20th Options Trading For Aprea Therapeutics (APRE)

Investors in Aprea Therapeutics Inc saw new options begin trading this week, for the May 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the APRE options chain...

APRE : 0.6661 (-0.34%)
Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Business Operations

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 0.6661 (-0.34%)
Aprea Therapeutics, Inc. (APRE) Loses 21.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Aprea Therapeutics, Inc. (APRE) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts...

APRE : 0.6661 (-0.34%)
Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More

Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.

BMY : 77.25 (+0.16%)
LLY : 307.70 (+0.57%)
MRNA : 130.90 (-0.88%)
APRE : 0.6661 (-0.34%)
FHTX : 12.04 (+1.43%)
Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azacitidine for Post-Transplant Maintenance Therapy in TP53 Mutant MDS and AML at the 2021 American Society of Hematology (ASH) Annual Meeting

60% relapse free survival at 1 year post-transplant79% overall survival at 1 year post-transplantMedian overall survival of 20.6 months BOSTON, Dec. ...

APRE : 0.6661 (-0.34%)
Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

AZN : 66.92 (+0.41%)
RHHBY : 43.3000 (+0.17%)
ABBV : 151.95 (+1.90%)
APRE : 0.6661 (-0.34%)
Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on Business Operations

BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 0.6661 (-0.34%)
Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd American Society of Hematology Annual Meeting

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical company focused on developing and commercializing...

APRE : 0.6661 (-0.34%)
Pre-Market Brief: U.S. Stocks to Open Higher on Strong U.S. Housing Data

Morning Markets Dec S&P 500 futures this morning are up by +0.62%. U.S. stock index futures are climbing today as the markets partially recover from Monday’s plunge on some dip-buying. Also, a rally...

JD : 50.39 (+1.63%)
PDD : 38.72 (+4.76%)
BABA : 82.81 (+0.41%)
NTES : 96.96 (+1.62%)
BIDU : 119.09 (+2.90%)
COP : 111.13 (+1.51%)
SRAD : 8.94 (+3.47%)
OXY : 66.36 (+1.98%)
LEN : 75.67 (+5.11%)
APRE : 0.6661 (-0.34%)
OEG : 0.9365 (-0.37%)
KAR : 15.24 (+2.97%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Aprea Therapeutics Inc. is a biopharmaceutical company. It is focused on developing and commercializing novel cancer therapeutics which reactivate the mutant tumor suppressor protein, p53. The Company's lead drug candidate, APR-246, a first-in-class small molecule p53 reactivator, is in clinical development...

See More

Key Turning Points

3rd Resistance Point 0.8449
2nd Resistance Point 0.8025
1st Resistance Point 0.7354
Last Price 0.6661
1st Support Level 0.6259
2nd Support Level 0.5835
3rd Support Level 0.5164

See More

52-Week High 7.8000
Fibonacci 61.8% 5.0572
Fibonacci 50% 4.2100
Fibonacci 38.2% 3.3628
Last Price 0.6661
52-Week Low 0.6200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar